Integra Lifesciences Holdings (Integra Lifesciences Holdings) Cash, Cash Equivalents, Marketable Securities : $309 Mil (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Integra Lifesciences Holdings Cash, Cash Equivalents, Marketable Securities?

Integra Lifesciences Holdings's quarterly cash, cash equivalents, marketable securities declined from Jun. 2023 ($309.19 Mil) to Sep. 2023 ($273.73 Mil) but then increased from Sep. 2023 ($273.73 Mil) to Dec. 2023 ($309.10 Mil).

Integra Lifesciences Holdings's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($513.45 Mil) to Dec. 2022 ($456.66 Mil) and declined from Dec. 2022 ($456.66 Mil) to Dec. 2023 ($309.10 Mil).

Integra Lifesciences Holdings Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Integra Lifesciences Holdings's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integra Lifesciences Holdings Cash, Cash Equivalents, Marketable Securities Chart

Integra Lifesciences Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

198.91

470.17

513.45

456.66

309.10

Integra Lifesciences Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															456.66	307.37	309.19	273.73	309.10

Integra Lifesciences Holdings Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Integra Lifesciences Holdings (NAS:IART) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Integra Lifesciences Holdings Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Integra Lifesciences Holdings's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Integra Lifesciences Holdings (Integra Lifesciences Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Integra Lifesciences Holdings Corp (NAS:IART) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

IL3:Germany

Address

1100 Campus Road, Princeton, NJ, USA, 08540

Website

https://www.integralife.com

Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman specialty surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.

Executives

Chantal Veillon-berteloot	officer: EVP & CHRO	1100 CAMPUS ROAD, PRINCETON NJ 08540
Jeffrey Mosebrook	officer: SVP, Fin & PAO	311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Lea Daniels Knight	officer: EVP & CFO	1100 CAMPUS ROAD, PRINCETON NJ 08540
Eric Schwartz	officer: Corp VP, Gen Counsel & Sec	C/O ERESEARCHTECHNOLOGY, INC., 1818 MARKET STREET, SUITE 1000, PHILADELPHIA PA 19103
Witte Jan De	director, officer: President & CEO	C/O RESMED INC., 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123
Michael J. Mcbreen	officer: Executive VP & President, CSS	1100 CAMPUS ROAD, PRINCETON NJ 08540
Harvinder Singh	officer: Exec VP & PRES, International	1100 CAMPUS ROAD, PRINCETON NJ 08540
Lisa Evoli	officer: Chief Human Resources Officer	311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Raymond G. Murphy	director	14604 CARROLTON ROAD, ROCKVILLE MD 20853
Renee Wonlai Lo	director	1100 CAMPUS ROAD, PRINCETON NJ 08540
Glenn Coleman	officer: CVP, CHIEF FINANCIAL OFFICER	C/O DENTSLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Tru St Partnership, L.p.	10 percent owner	795 EAST LANCASTER AVE., STE. 200, VILLANOVA PA 19085
Peter J Arduini	officer: President & COO	311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Shaundra Clay	director	1100 CAMPUS ROAD, PRINCETON NJ 08540
Stuart Essig	director, officer: President and CEO	311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536